ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
Multiple sclerosis
consensus
disease-modifying therapy
infections
vaccination
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
medline:
12
7
2023
pubmed:
9
6
2023
entrez:
9
6
2023
Statut:
ppublish
Résumé
With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy. To develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs). This work was conducted by a multidisciplinary working group using formal consensus methodology. Clinical questions (defined as population, interventions, and outcomes) considered all authorized DMTs and vaccines. A systematic literature search was conducted and quality of evidence was defined according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence. The recommendations were formulated based on the quality of evidence and the risk-benefit balance. Seven questions, encompassing vaccine safety, vaccine effectiveness, global vaccination strategy and vaccination in sub-populations (pediatric, pregnant women, elderly and international travelers) were considered. A narrative description of the evidence considering published studies, guidelines, and position statements is presented. A total of 53 recommendations were agreed by the working group after three rounds of consensus. This first European consensus on vaccination in pwMS proposes the best vaccination strategy according to current evidence and expert knowledge, with the goal of homogenizing the immunization practices in pwMS.
Sections du résumé
BACKGROUND
With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy.
OBJECTIVE
To develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs).
METHODS
This work was conducted by a multidisciplinary working group using formal consensus methodology. Clinical questions (defined as population, interventions, and outcomes) considered all authorized DMTs and vaccines. A systematic literature search was conducted and quality of evidence was defined according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence. The recommendations were formulated based on the quality of evidence and the risk-benefit balance.
RESULTS
Seven questions, encompassing vaccine safety, vaccine effectiveness, global vaccination strategy and vaccination in sub-populations (pediatric, pregnant women, elderly and international travelers) were considered. A narrative description of the evidence considering published studies, guidelines, and position statements is presented. A total of 53 recommendations were agreed by the working group after three rounds of consensus.
CONCLUSION
This first European consensus on vaccination in pwMS proposes the best vaccination strategy according to current evidence and expert knowledge, with the goal of homogenizing the immunization practices in pwMS.
Identifiants
pubmed: 37293841
doi: 10.1177/13524585231168043
pmc: PMC10338708
doi:
Types de publication
Journal Article
Review
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
904-925Commentaires et corrections
Type : CommentIn
Références
Eur J Neurol. 2013 Jun;20(6):975-80
pubmed: 23521577
J Clin Pharmacol. 2012 Dec;52(12):1879-90
pubmed: 22174429
Neurology. 2014 Jan 7;82(1):41-8
pubmed: 24306002
Neurology. 1997 Feb;48(2):312-4
pubmed: 9040712
J Neurol Neurosurg Psychiatry. 2022 Apr;93(4):448-450
pubmed: 34408003
JAMA Neurol. 2021 Dec 1;78(12):1529-1531
pubmed: 34554185
Neurol Neuroimmunol Neuroinflamm. 2020 Jan 9;7(2):
pubmed: 31919278
Mult Scler. 2022 Nov;28(13):2151-2153
pubmed: 35672923
Nat Rev Neurol. 2012 Jan 24;8(3):143-51
pubmed: 22270022
Ann Rheum Dis. 2020 Jan;79(1):39-52
pubmed: 31413005
Neurology. 2013 Sep 3;81(10):872-6
pubmed: 23925762
Hum Vaccin Immunother. 2020 Aug 2;16(8):1900-1904
pubmed: 31977283
Paediatr Child Health. 2018 Jul;23(4):262-265
pubmed: 30657133
J Cent Nerv Syst Dis. 2021 Dec 02;13:11795735211060118
pubmed: 34880703
Neurology. 2015 Mar 3;84(9):872-9
pubmed: 25636714
PLoS One. 2021 Jan 15;16(1):e0244986
pubmed: 33449966
Pract Neurol. 2020 Dec;20(6):435-445
pubmed: 32632038
Neurology. 1999 Oct 22;53(7):1588-9
pubmed: 10534275
Pediatrics. 2016 Jul;138(1):
pubmed: 27358474
Neurology. 2022 Feb 1;98(5):e541-e554
pubmed: 34810244
CMAJ Open. 2021 May 14;9(2):E510-E521
pubmed: 33990365
Acad Med. 2016 May;91(5):663-8
pubmed: 26796090
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835
pubmed: 34035836
Mult Scler. 2012 Feb;18(2):254-6
pubmed: 21828198
Front Immunol. 2021 Dec 09;12:781843
pubmed: 34956211
J Neurol. 2011 Aug;258(8):1545-7
pubmed: 21336784
Ann Neurol. 2022 Mar;91(3):342-352
pubmed: 35067959
Arch Neurol. 2011 Oct;68(10):1267-71
pubmed: 21670384
Mult Scler Relat Disord. 2021 Oct;55:103157
pubmed: 34418737
Neurotherapeutics. 2022 Jan;19(1):325-333
pubmed: 34859382
Curr Infect Dis Rep. 2017 Feb;19(2):7
pubmed: 28233190
PLoS One. 2013 Nov 05;8(11):e78532
pubmed: 24223820
J Neurol Neurosurg Psychiatry. 2022 Sep;93(9):986-994
pubmed: 35688629
J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):19-22
pubmed: 34670844
BMJ. 2021 Feb 22;372:n188
pubmed: 33619170
Mult Scler. 2021 Mar;27(3):347-359
pubmed: 32940128
EBioMedicine. 2021 Nov;73:103636
pubmed: 34666226
Can J Infect Dis. 1996 Sep;7(5):303-6
pubmed: 22514454
J Neurol. 1995 Feb;242(3):143-6
pubmed: 7751856
Nat Rev Neurol. 2022 May;18(5):289-306
pubmed: 35388213
Mult Scler. 2021 Dec;27(14):2280-2283
pubmed: 33870792
Mayo Clin Proc. 2019 Nov;94(11):2314-2339
pubmed: 31685156
Mult Scler Relat Disord. 2019 Jun;31:173-188
pubmed: 31159998
EBioMedicine. 2021 Oct;72:103581
pubmed: 34563483
Mult Scler. 2002 May;8(3):237-42
pubmed: 12120696
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
Ann Neurol. 2022 Jan;91(1):89-100
pubmed: 34687063
Clin Geriatr Med. 2018 Feb;34(1):131-143
pubmed: 29129213
Int Nurs Rev. 2012 Sep;59(3):305-11
pubmed: 22897180
Vaccines (Basel). 2021 Dec 11;9(12):
pubmed: 34960216
J Neurol. 2022 Jan;269(1):55-58
pubmed: 34115170
Neurol Neuroimmunol Neuroinflamm. 2020 May 1;7(4):
pubmed: 32358223
J Neuroimmunol. 2021 Dec 15;361:577746
pubmed: 34655991
JAMA Neurol. 2021 Dec 1;78(12):1510-1514
pubmed: 34554197
Mult Scler Relat Disord. 2021 Jun;51:102906
pubmed: 33827005
Neurol Neuroimmunol Neuroinflamm. 2017 Sep 13;4(6):e398
pubmed: 28955715
Neurology. 2013 Aug 6;81(6):552-8
pubmed: 23851964
J Clin Neurosci. 2022 Oct;104:118-125
pubmed: 36029752
J Neurol Sci. 2014 Jun 15;341(1-2):22-7
pubmed: 24731783
Vaccines (Basel). 2021 Jul 11;9(7):
pubmed: 34358189
Lancet Rheumatol. 2021 Nov;3(11):e789-e797
pubmed: 34514436
Obstet Gynecol. 2018 May;131(5):799-802
pubmed: 29630014
Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(2):e70
pubmed: 25738167
N Engl J Med. 2001 Feb 1;344(5):319-26
pubmed: 11172162
Mult Scler. 1997 Aug;3(4):243-7
pubmed: 9372507
J Virol. 2007 Feb;81(4):2025-30
pubmed: 17151098
Vaccine. 2003 Apr 1;21 Suppl 1:S56-61
pubmed: 12628815
Neurol Neuroimmunol Neuroinflamm. 2017 Nov 15;5(1):e409
pubmed: 29159204
Mult Scler. 2014 Jul;20(8):1074-80
pubmed: 24436455
Neurology. 2005 Dec 27;65(12):1964-6
pubmed: 16380621
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Nat Rev Neurol. 2021 Dec;17(12):729-730
pubmed: 34686837
Neurol Neuroimmunol Neuroinflamm. 2014 Sep 11;1(3):e28
pubmed: 25340080
Neurol Res. 2012 Sep;34(7):730-3
pubmed: 22709910
Ann Neurol. 2022 Jun;91(6):796-800
pubmed: 35243687
Arthritis Rheum. 2010 Jan;62(1):64-74
pubmed: 20039397
Blood Adv. 2021 Jun 21;5(12):2624-2643
pubmed: 34152403
J Neurol Sci. 2012 Mar 15;314(1-2):102-3
pubmed: 22056469
J Neurol. 2021 Nov;268(11):3961-3968
pubmed: 33844056
Clin Infect Dis. 2014 Feb;58(3):309-18
pubmed: 24421306
CNS Neurosci Ther. 2019 Feb;25(2):245-254
pubmed: 30044050
Neurology. 2020 Oct 6;95(14):e1999-e2008
pubmed: 32727835
Proc Natl Acad Sci U S A. 2019 Dec 17;116(51):25800-25807
pubmed: 31748274
Neurology. 2019 Sep 24;93(13):584-594
pubmed: 31462584
J Can Assoc Gastroenterol. 2019 Dec;2(4):149-152
pubmed: 31616855
Neurology. 2001 Apr 10;56(7):938-43
pubmed: 11294933
Obstet Gynecol. 2015 Jan;125(1):212-226
pubmed: 25560127
BMC Infect Dis. 2019 Aug 2;19(1):683
pubmed: 31375073
Neurology. 2002 Dec 24;59(12):1837-43
pubmed: 12499473
Ann Neurol. 2011 Feb;69(2):408-13
pubmed: 21387383
Eur J Neurol. 2018 Mar;25(3):527-534
pubmed: 29205701
Nat Rev Neurol. 2019 Jun;15(6):329-342
pubmed: 31000816
Lancet Infect Dis. 2019 Jun;19(6):e200-e212
pubmed: 30744963
Int J Clin Pharm. 2016 Jun;38(3):655-62
pubmed: 26846316
Neurologia (Engl Ed). 2021 Jan - Feb;36(1):50-60
pubmed: 32561334
Hum Vaccin Immunother. 2016 Aug 2;12(8):1972-1981
pubmed: 27385070